Time New York: Sun 04 Dec 17:22 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Allergan’s Belkyra Gets Swedish Approval for Double Chin

Zacks

Allergan plc AGN announced that its prescription medicine, Belkyra (deoxycholic acid), has been granted marketing approval in Sweden for the treatment of moderate-to-severe fullness under the chin in adults, commonly referred to as double chin.

Belkyra was added to Allergan’s portfolio after the acquisition of Kythera Biopharmaceuticals in Oct 2015. In the U.S. and Canada, Belkyra is marketed under the trade name Kybella. It is also licensed in 10 other countries across the globe.

Belkyra was granted the Swedish Marketing Authorisation following an approval by the Swedish Medical Products Agency (MPA).

Belkyra is the first and only FDA-approved non-surgical injectable treatment for the reduction of moderate-to-severe submental fullness.

Note that Belkyra was evaluated in four phase III clinical studies involving more than 2,600 patients worldwide, two each in North America and Europe. Results from the studies demonstrated a high overall efficacy rate, as shown by a 1-grade improvement in fullness under the chin at 12 weeks after the last treatment. While European studies recorded a 63.8% improvement, North American trials witnessed a 78.5% improvement. Moreover, both the studies saw better improvement in the psychological impact caused by the fullness when treated with Belkyra compared to placebo.

According to data provided by the American Society for Dermatologic Surgery (ASDS), 67% of people with a double chin are bothered by the condition. Assuming further approvals in other European countries in the coming months, Allergan expects Belkyra to generate substantial revenues. Allergan’s prospects are quite impressive as well. The company has been actively pursuing acquisitions over the past few years and has been working on expanding its presence in the branded market. It is also working on expanding the labels of marketed products like Botox, Linzess and Restasis. It primarily focuses on core therapeutic areas like eye care, aesthetics, CNS, GI, anti-infectives, women's health and urology.

ALLERGAN PLC Price

ALLERGAN PLC Price | ALLERGAN PLC Quote


Zacks Rank & Key Picks

Allergan currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. BMRN, Exelixis, Inc. EXEL and Amarin Corporation plc AMRN. While BioMarin and Exelixis sport a Zacks Rank #1 (Strong Buy), Amarin carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Amarin’s loss estimates have narrowed from 53 cents to 40 cents for 2016 and from 36 cents to 27 cents for 2017 over the last 60 days. The company’s share price has soared 65.1% year to date.

BioMarin’s loss estimates have narrowed from 28 cents to 27 cents for 2016 and from $1.16 to $1.12 for 2017 over the last 60 days.

Exelixis’ loss estimates have narrowed from 76 cents to 63 cents for 2016 and from 22 cents to 3 cents for 2017 over the last 60 days. The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price skyrocketed 100.7% year to date.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.